- Home
- EXLS vs LEGN Comparison
EXLS vs LEGN Comparison
Compare EXLS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXLS | LEGN |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXLS | LEGN |
|---|---|---|
| Price | $30.92 | $18.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $46.80 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $2,087,679,000.00 | N/A |
| Revenue This Year | $12.66 | $43.65 |
| Revenue Next Year | $10.54 | $32.75 |
| P/E Ratio | $20.07 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $26.94 | $16.24 |
| 52 Week High | $48.79 | $45.30 |
Technical Indicators
Market Signals| Indicator | EXLS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 56.74 |
| Support Level | $28.62 | $17.46 |
| Resistance Level | $31.50 | $20.39 |
| Average True Range (ATR) | 0.93 | 0.70 |
| MACD | 0.19 | 0.15 |
| Stochastic Oscillator | 74.66 | 91.73 |
Price Performance
Historical ComparisonAbout EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.